SCHEMBL2117866

SCHEMBL2117866

Cc1ccc(-c2ccco2)cc1N(C)S(=O)(=O)c1ccc(N)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.47
LMNA P02545 1/20 0.41
CYP2C9 P11712 3/20 0.40
C5AR1 P21730 1/20 0.40
CYP2C8 P10632 1/20 0.38
CYP2C18 P33260 1/20 0.38
PIK3CD O00329 1/20 0.38
KMT2A Q03164 2/20 0.37
GAA P10253 1/20 0.37
C1R P00736 1/20 0.37
PRSS1 P07477 1/20 0.37
TRIM24 O15164 1/20 0.37
UBE2I P63279 1/20 0.36
SAE1 Q9UBE0 1/20 0.36
UBA2 Q9UBT2 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2117311 0.88 HSD17B1 (0.43) LMNACYP2C9C5AR1KMT2AGAA
SCHEMBL2118249 0.88 PSEN1 (0.45) LMNACYP2C9C5AR1PIK3CDKMT2A
SCHEMBL2118388 0.80 LMNA (0.41) LMNACYP2C9C5AR1CYP2C8CYP2C18
SCHEMBL2117541 0.79 ACSS2 (0.40) LMNACYP2C9TRIM24KDM4EPOLB
SCHEMBL2117226 0.78 CYP2C9 (0.39) LMNACYP2C9KMT2ATRIM24UBE2I
SCHEMBL2118443 0.77 LMNA (0.38) LMNACYP2C9C5AR1CYP2C8CYP2C18
SCHEMBL2120046 0.77 CYP2C9 (0.37) LMNACYP2C9PIK3CDKMT2AUBE2I
SCHEMBL2122135 0.76 LMNA (0.41) LMNACYP2C9C5AR1PIK3CDGAA
SCHEMBL2120619 0.75 TRIM24 (0.57) TAAR1KMT2ATRIM24MEN1ALDH1A1
SCHEMBL2119431 0.75 LMNA (0.41) LMNACYP2C9C5AR1PIK3CDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1AN, HIF1A, EGLN2 TAAR1 4100/4885LMNA 2529/4885CYP2C9 3693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.